medigraphic.com
ISSN 1729-519X (Print)

2020, Number 4

<< Back Next >>

Revista Habanera de Ciencias Médicas 2020; 19 (4)

Effects of Epidermal growth factor on histological features of the kidney in rats with Chronic kidney failure

Núñez CCR, Zumeta DMT, Pazo BN, Iglesias DE

Language: Spanish
References: 30
Page: 1-15
PDF size: 1156.37 Kb.


ABSTRACT

Introduction: Chronic Kidney Failure is a public health problem; therefore, the need for actions aimed at its prevention, diagnosis and effective therapeutic interventions is a most. Recent studies use the Epidermal Growth Factor to evaluate its reno-protective effect on functional variables; however, there are no studies related to the effects of this product on histological features of kidney in chronic failure.
Objective: To determine the possible protective and / or repair effects of recombinant human epidermal growth factor on the histological features of kidneys in chronic renal failure.
Material and methods: We worked with three series, each consisting of a control group and an experimental group of five animals. The experimental groups underwent 5/6 surgical ablation of the renal mass. Series A consisted of control animals, series B included those animals treated with Epidermal Growth Factor 24 hours before the procedure and series C was made up of those animals treated with the bioproduct 24 hours after the procedure. Fifty-six days after surgical act, euthanasia was practiced on the animals and the kidneys were histologically studied.
Results: Histological alterations were observed in the renal corpuscles and tubules in the animals included in series A; in series B it was observed that most of the renal parenchyma presented normal characteristics and those in series C showed increased kidney damage.
Conclusions: Recombinant human epidermal growth factor has a reno-protective effect; however, it does not offer a repair effect of acute kidney.


REFERENCES

  1. Martínez Castelao A, Górriz JL, Bover J, Segura de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Aten Primaria. 2014 Nov;46(9):501-19.

  2. Salvador González B, Rodríguez Pascual M, Ruipérez Guijarro L, Ferré González A, Cunillera Puertolas O, Rodríguez Latre LM. Enfermedad renal crónica en Atención Primaria: prevalencia y factores de riesgo asociados. Aten Primaria. 2015 Apr;47(4):236-45.

  3. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019 [Internet]. La Habana: Ministerio de Salud Pública; 2019 [Citado 14/10/2019]. Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2019-ed-2020.pdf

  4. Magrans Buch Ch, Barranco Hernández E, Ibars Blañoz EV. Hemodiálisis y Enfermedad Renal Crónica. La Habana: ECIMED; 2016.

  5. Bencomo DT, Brito S del R, González TM. Efecto del Factor de crecimiento epidérmico humano recombinante en estadios iniciales de insuficiencia renal crónica experimental. Resumen. Rev Habanera Cienc Médicas [Internet]. 2005 [Citado 30/11/2017];4(5):[Aprox. 2 p.]. Disponible en: Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/841

  6. Pérez García CC. Biomodelos experimentales en la insuficiencia renal crónica [Internet]. Madrid: Real Academia de Ciencias Veterinarias; 1995 [Citado 26/11/2018]. Disponible en: http://www.racve.es/publicaciones/biomodelos-experimentales-en-la-insuficiencia-renal-cronica/

  7. Agaty SM. Triiodothyronine attenuates the progression of renal injury in a rat model of chronic kidney disease. Can J Physiol Pharmacol. 2018 Jun;96(6):603-10.

  8. Fujihara CK, Kowala MC, Breyer MD, Sena CR, Rodríguez MV, Arias SCA, et al. A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy. Sci Rep. 2017 Aug 11;7(1):7899.

  9. Van Koppen A, Verhaar MC, Bongartz LG, Joles JA. 5/6th nephrectomy in combination with high salt diet and nitric oxide synthase inhibition to induce chronic kidney disease in the Lewis rat. J Vis Exp Jove. 2013 Jul; (77):e50398.

  10. Pawlak D, Domaniewski T, Znorko B, Oksztulska Kolanek E, Lipowicz P, Doroszko M, et al. The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. BONE. 2017 Dec;105:1-10.

  11. Saracyn M, Czarzasta K, Brytan M, Murawski P, Lewicki S, Zabkowski T, et al. Role of Nitric Oxide Pathway in Development and Progression of Chronic Kidney Disease in Rats Sensitive and Resistant to its Occurrence in an Experimental Model of 5/6 Nephrectomy. Med Sci Monit [Internet].2017 Oct [Citado 26/11/2018];23:4865-73. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649515/

  12. Lai WS, Rais Bahrami S. Safety and Efficacy of En Bloc Renal Hilar Vascular Staple Ligation: A Meta-Analysis. J Urol. 2017 Jan;197(1):175-81.

  13. Núñez Cairo CR. Biomodelo de insuficiencia renal crónica con el uso del tisuacryl en ratas. Rev Habanera Cienc Médicas [Internet]. 2012 [Citado 26/11/2018];11(5):593-604. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/1948

  14. Núñez Cairo CR. Reno-protective and reno-restorative effect of the Epidermal Growth Factor in the biomodel of Chronic Renal Failure. Rev Habanera Cienc Médicas [Internet]. 2017 [Citado 26/11/2018];16(6):1032-43. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/2144

  15. Salama AD, Cook HT. The Renal Biopsy. In: Taal MW, Chertow GM, Marsden PA, Sckorecki K, Yu A SL. Brenner and Rector´s The Kidney. 10 ed [Internet]. Amsterdam: Elsevier; 2011. p. 2962-72 [Citado 26/11/2018]. Disponible en: Disponible en: https://www.us.elsevierhealth.com/brenner-and-rectors-the-kidney-2-volume-set-9781455748365.html

  16. Conn H. Biological Stain Geneva NY Biotech Publication 1953. In: Gretchem L. Animal Tissue Techniques [Internet]. London: WH Freeman and company; 1962. p.809-23 [Citado 26/11/2018]. Disponible en:https://pdfslide.net/documents/animal-tissue-techniques-1962.html

  17. Kumar V, Abbas AK, Aster JC, eds. Kidney and Its Collecting System. En su: Robbins Basic Pathology. 9 ed [Internet]. Philadelphia: Saunders; 2013. p. 734-76. [Citado 26/11/2018]. Disponible en: Disponible en: https://www.elsevier.com/books/robbins-basic-pathology/kumar/978-1-4377-1781-5

  18. Cohen A. Renal Anatomy and Basic Concepts and Methods in Renal Pathology. En su: Fundamentals of Renal Pathology [Citado 26/11/2018]. New York: Springer Science Business Media; 2006. p. 608-23. Disponible en: Disponible en: https://www.springer.com/gp/book/9780387311272

  19. Carrera M, Poveda R. Histología renal y morfometría del intersticio en pacientes nefróticos tratados con ciclosporina. Nefrología [Internet]. 1995 [Citado 24/05/2016];15(3):[Aprox. 2 p.]. Disponible en: http://www.revistanefrologia.com/es-publicacion-nefrologia-articulo-histologia-renal-morfometria-del-intersticio-pacientes-nefroticos-tratados-con-ciclosporina-X0211699595007499

  20. Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017 May;119(5):661-6.

  21. Yen TH, Alison MR, Goodlad RA, Otto WR, Jeffery R, Cook HT, et al. Epidermal growth factor attenuates tubular necrosis following mercuric chloride damage by regeneration of indigenous, not bone marrow-derived cells. J Cell Mol Med. 2015 Feb;19(2):463-73.

  22. Rodríguez Salgueiro S, González Núñez L, García Del Barco Herrera D, Santos Febles E, Maza Ares D, Millares López R, et al. Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats. Iran J Kidney Dis. 2014 Sep;8(5):382-8.

  23. Berlanga Acosta J, Fernández Montequín J, Valdés Pérez C, Savigne Gutiérrez W, Mendoza Marí Y, García Ojalvo A, et al. Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. BioMed Res Int. 2017 Aug; 21:1-10.

  24. Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, et al. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev. 2013 Jan;15(1):11-5.

  25. Berlanga J. Heberprot-P: antecedentes experimentales y bases farmacológicas. Biotecnol Apl [Internet]. 2010 [Citado 24/05/2016];.27(2):88-94. Disponible en: https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2010/27/2/BA002702RV081-087.pdf

  26. Perez Saad H, Subiros N, Berlanga J, Aldana L, Garcia Del Barco D. Neuroprotective effect of epidermal growth factor in experimental acrylamide neuropathy: an electrophysiological approach. J Peripher Nerv Syst JPNS. 2017 Jun;22(2):106-11.

  27. Valenzuela Silva CM, Tuero Iglesias AD, García Iglesias E, González Díaz O, del Río Martí A, Year Alos IB, et al. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care [Internet]. 2012 [Citado 24/05/2016];35:[Aprox. 2 p.]. Disponible en:https://www.ncbi.nlm.nih.gov/pubmed/22966096

  28. Hotchkiss H, Chu TT, Hancock WW, Schröppel B, Kretzler M, Schmid H, et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation. 2006 Feb;81(3):342-9.

  29. Cornejo Uribe R. El factor de crecimiento epidérmico y la diferenciación celular del epitelio mamario. Int J Morphol. 2011;29(3):821-4.

  30. Lamb EJ, Levey AS, Stevens PE. The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution. Clin Chem. 2013 Mar;59(3):462-5.




2020     |     www.medigraphic.com